Antimicrob Agents Chemother ; 57 7 :Jul. The distribution of AZI in proinflammatory cells may be important to the anti-inflammatory properties. Previous studies have described plasma AZI pharmacokinetics.
The objective of this study was to describe sarcoma cancer buttocks pharmacokinetics of AZI in whole blood concentration in whole blood [Cb] and plasma concentration in plasma [Cp] of healthy subjects. In this study, 12 subjects received AZI mg once a day for 3 days. AZI Cb and Cp were quantified in serial samples collected up to 3 weeks after the last dose and analyzed using noncompartmental and compartmental methods.
After the last dose, Cb was greater than Cp. Importantly, Cb, but not Cp, was quantifiable in all but one subject at 3 weeks.
The blood area under the curve during a h dosing interval AUC24 was â¼2-fold greater than the plasma AUC24, but simulations suggested that Cb was not at steady state by day 3.
Upon exploration of numerous models, an empirical 3-compartment model adequately described Cp and Cb, but Cp was somewhat underestimated.
Plasma, peripheral, and cell compartmental volumes were liters, 2, liters, and 3, liters, respectively. Interindividual variability in CL was low This is the first report to describe AZI Cb in healthy subjects, the distribution parameters between Cp and Cb, and AZI retention in blood for up to 3 weeks following 3 daily doses. This study has been registered at Sarcoma cancer buttocks.